1
|
Alshora D, Ibrahim M, Alanazi N, Alowyid M, Ali Alnakhli Z, Mohammed Alshiban N, Maodaa S, Alyami NM, Alotaibi I. Formulation of Glibenclamide proniosomes for oral administration: Pharmaceutical and pharmacodynamics evaluation. Saudi Pharm J 2023; 31:101830. [PMID: 38028219 PMCID: PMC10666557 DOI: 10.1016/j.jsps.2023.101830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 10/13/2023] [Indexed: 12/01/2023] Open
Abstract
Glibenclamide (GB), oral antidiabetic sulfonylurea, is used in the management of diabetes mellitus type II. It suffers from low bioavailability due to low water solubility. This work aimed to enhance the dissolution of GB by formulating the drug as a proniosomes which then improves the pharmacological effect. GB proniosomal formulations were prepared using a slurry method with sucrose as a carrier. The formulations were characterized by particle size, zeta potential, entrapment efficiency %, flow properties of the powder, and in vitro dissolution study. The pharmacological effect was also assessed by determining and measuring the fasting blood glucose level (BGL) before and after the treatment. Formulating GB proniosomes with the slurry method produces a free-flowing powder with a particle size range from 190.050 ± 43.204 to 1369.333 ± 150.407 nm and the zeta potential was above 20 mV (-24 to -58 mV), indicating good stability. The dissolution rate for all formulations was higher than that of the pure drug, indicating the efficiency of the proniosome in enhancing the drug solubility. A significant reduction in the fasting blood glucose level (73 %) was observed in animals treated with proniosomal formulation with no sign of liver damage. In contrast, the pharmacodynamics results show a significant reduction in fasting blood glucose level for animals treated with proniosomes compared to a 17.6 % reduction in BGL after treatment with pure drug. Moreover, the histopathological results showed no sign of liver damage that occurred with proniosomal treatment. GB proniosomal formulations is a promising drug delivery system with good therapeutic efficacy and stability.
Collapse
Affiliation(s)
- Doaa Alshora
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Mohamed Ibrahim
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Nouf Alanazi
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Malak Alowyid
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Zainab Ali Alnakhli
- Department of Zoology, College of Science, King Saud University, PO Box -2455, Riyadh 11451, Saudi Arabia
| | - Noura Mohammed Alshiban
- Department of Zoology, College of Science, King Saud University, PO Box -2455, Riyadh 11451, Saudi Arabia
| | - Saleh Maodaa
- Department of Zoology, College of Science, King Saud University, PO Box -2455, Riyadh 11451, Saudi Arabia
| | - Nouf M. Alyami
- Department of Zoology, College of Science, King Saud University, PO Box -2455, Riyadh 11451, Saudi Arabia
| | - Ibrahim Alotaibi
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| |
Collapse
|
2
|
Wei Chen H, Po Fang W. A novel method for the microencapsulation of curcumin by high-pressure processing for enhancing the stability and preservation. Int J Pharm 2021; 613:121403. [PMID: 34933079 DOI: 10.1016/j.ijpharm.2021.121403] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 12/04/2021] [Accepted: 12/15/2021] [Indexed: 11/25/2022]
Abstract
Curcumin is used for the development of new pharmaceutical and food products, but its application is generally hindered by the poor solubility of curcumin and thermal instability during storage and processing. In this study, the liposomes of curcumin (cur-liposomes) were prepared by a novel combination of ethanol injection and high-pressure processing (HPP) to enhance the stability and preservation of curcumin. The pasteurization, mean particle size, size distribution, and encapsulation efficiency of cur-liposomes and the kinetics of their thermal degradation were also investigated in this research. From the results, the kinetic rate constants of curcumin in samples of free curcumin and cur-liposome at 25 °C were found to be 1.6 × 10-3 and 0.8 × 10-3 min-1, respectively. The phospholipid bilayer structure could protect curcumin. The results propose that the HPP method for liposome preparation is superior to the probe-sonication method in terms of stability, encapsulation efficiency, and homogeneity. Furthermore, the preparation of cur-liposomes by HPP with a hydrostatic pressure of 200 MPa could maintain the optimal particle size (206.4 nm) and polydispersity index (0.19). Conclusively, the combination of ethanol injection and HPP can not only successfully inactivate the microorganisms during liposome preparation for microencapsulation of bioactive compounds but also effectively preventthe thermal degradation of heat-sensitive substances in non-thermal processing for practical applications.
Collapse
Affiliation(s)
- Hua Wei Chen
- Department of Chemical and Materials Engineering, National Ilan University, 1, Sec. 1, Shen-Lung Road, Yilan 260, Taiwan, Republic of China.
| | - Wu Po Fang
- Department of Chemical and Materials Engineering, National Ilan University, 1, Sec. 1, Shen-Lung Road, Yilan 260, Taiwan, Republic of China
| |
Collapse
|
3
|
Simulation, In Vitro, and In Vivo Cytotoxicity Assessments of Methotrexate-Loaded pH-Responsive Nanocarriers. Polymers (Basel) 2021; 13:polym13183153. [PMID: 34578054 PMCID: PMC8471936 DOI: 10.3390/polym13183153] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 09/13/2021] [Accepted: 09/14/2021] [Indexed: 12/19/2022] Open
Abstract
In this study, pH-responsive niosomal methotrexate (MTX) modified with ergosterol was prepared for potential anticancer application. The prepared formulation had a size of 176.7 ± 3.4 nm, zeta potential of −31.5 ± 2.6 mV, EE% of 76.9 ± 2.5%, and a pH-responsive behavior in two different pHs (5.4 and 7.4). In-silico evaluations showed that MTX intended to make a strong hydrogen bond with Span 60 compartments involving N2 and O4 atoms in glutamic acid and N7 atom in pteridine ring moieties, respectively. The cytotoxic effects of free and pH-MTX/Nio were assessed against MCF7 and HUVECs. Compared with free MTX, we found significantly lower IC50s when MCF7 cells were treated with niosomal MTX (84.03 vs. 9.464 µg/mL after 48 h, respectively). Moreover, lower cell killing activity was observed for this formulation in normal cells. The pH-MTX/Nio exhibited a set of morphological changes in MCF7 cells observed during cell death. In-vivo results demonstrated that intraperitoneal administration of free MTX (2 mg/kg) after six weeks caused a significant increase in serum blood urea nitrogen (BUN), serum creatinine, and serum malondialdehyde (MDA) levels of rats compared to the normal control rats. Treatment with 2 and 4 mg/kg doses of pH-MTX/Nio significantly increased serum BUN, serum creatinine, and serum lipid peroxidation. Still, the safety profile of such formulations in healthy cells/tissues should be further investigated.
Collapse
|
4
|
de Barros C, Aranha N, Severino P, Souto EB, Zielińska A, Lopes A, Rios A, Batain F, Crescencio K, Chaud M, Alves T. Quality by Design Approach for the Development of Liposome Carrying Ghrelin for Intranasal Administration. Pharmaceutics 2021; 13:pharmaceutics13050686. [PMID: 34068793 PMCID: PMC8151022 DOI: 10.3390/pharmaceutics13050686] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Revised: 05/02/2021] [Accepted: 05/04/2021] [Indexed: 02/06/2023] Open
Abstract
The therapeutic use of peptides has increasingly recognized in the development of new therapies. However, the susceptible enzymatic cleavage is a barrier that needs to overcome. Nose-to-brain delivery associated with liposomes can protect peptides against biodegradation and improve the accessibility to brain targets. The aim was to develop a liposomal formulation as ghrelin carrier. The quality by design (QbD) approach was used as a strategy for method development. The initial risk assessments were carried out using a fishbone diagram. A screening design study was performed for the critical material attributes/critical process parameters (CMAs/CPPs) on critical quality attributes (CQAs). Liposomes were obtained by hydrating phospholipid films, followed by extrusion or homogenization, and coated with chitosan. The optimized liposome formulation was produced by high-pressure homogenization coated with chitosan, and the resulted were liposomes size 72.25 ± 1.46 nm, PDI of 0.300 ± 0.027, the zeta potential of 50.3 ± 1.46 mV, and encapsulation efficiency of 53.2%. Moreover, chitosan coating improved performance in ex vivo permeation and mucoadhesion analyzes when compared to the uncoated liposome. In this context, chitosan coating is essential for the performance of the formulations in the ex vivo permeation and mucoadhesion analyzes. The intranasal administration of ghrelin liposomes coated with chitosan offers an innovative opportunity to treat cachexia.
Collapse
Affiliation(s)
- Cecília de Barros
- Laboratory of Biomaterials and Nanotechnology (LaBNUS), University of Sorocaba, Sorocaba 18078-005, São Paulo, Brazil; (C.d.B.); (A.R.); (F.B.); (K.C.)
| | - Norberto Aranha
- Technological and Environmental Processes, University of Sorocaba, Sorocaba 18078-005, São Paulo, Brazil;
| | - Patrícia Severino
- Nanomedicine and Nanotechnology Laboratory (LNMed), Institute of Technology and Research (ITP), Av. Murilo Dantas, 300, Aracaju 49010-390, Sergipe, Brazil;
| | - Eliana B. Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Ciências da Saúde, 3000-548 Coimbra, Portugal;
| | - Aleksandra Zielińska
- Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland;
| | - André Lopes
- Faculty of Pharmaceutical Science, University of Campinas, Campinas 13083-871, São Paulo, Brazil;
| | - Alessandra Rios
- Laboratory of Biomaterials and Nanotechnology (LaBNUS), University of Sorocaba, Sorocaba 18078-005, São Paulo, Brazil; (C.d.B.); (A.R.); (F.B.); (K.C.)
| | - Fernando Batain
- Laboratory of Biomaterials and Nanotechnology (LaBNUS), University of Sorocaba, Sorocaba 18078-005, São Paulo, Brazil; (C.d.B.); (A.R.); (F.B.); (K.C.)
| | - Kessi Crescencio
- Laboratory of Biomaterials and Nanotechnology (LaBNUS), University of Sorocaba, Sorocaba 18078-005, São Paulo, Brazil; (C.d.B.); (A.R.); (F.B.); (K.C.)
| | - Marco Chaud
- Laboratory of Biomaterials and Nanotechnology (LaBNUS), University of Sorocaba, Sorocaba 18078-005, São Paulo, Brazil; (C.d.B.); (A.R.); (F.B.); (K.C.)
- Technological and Environmental Processes, University of Sorocaba, Sorocaba 18078-005, São Paulo, Brazil;
- College of Bioprocess and Biotechnology Engineering, University of Sorocaba, Sorocaba 18023-000, Sâo Paulo, Brazil
- Correspondence: (M.C.); (T.A.)
| | - Thais Alves
- Laboratory of Biomaterials and Nanotechnology (LaBNUS), University of Sorocaba, Sorocaba 18078-005, São Paulo, Brazil; (C.d.B.); (A.R.); (F.B.); (K.C.)
- Technological Innovation Agency of Sorocaba, Sorocaba Technology Park, Itavuvu Avenue, Sorocaba 18078-005, São Paulo, Brazil
- Correspondence: (M.C.); (T.A.)
| |
Collapse
|
5
|
Alp G, Oztas Y. Facile L-Glutamine delivery to erythrocytes via DOPC-DPPG mixed liposomes. J Liposome Res 2021; 31:409-419. [PMID: 33944651 DOI: 10.1080/08982104.2021.1918152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Sickle cell disease (SCD) is a mortal erythrocyte-based disease which is hard to treat effectively. Development of a treatment method that can prevent deoxygenation of erythrocytes or reduce the oxidative stress of sickle erythrocytes is one of the important issues towards SCD. Among a wide variety of potential drug carriers, liposomes are advantageous and preferable with their easy preparation and biocompatibility. In this study, L-Glutamine (Gln) loaded liposomes were prepared with 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-Dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DPPG). Liposomes were characterized via zeta potential, size measurements, differential scanning calorimetry, Fourier Transform Infra-red Spectroscopy and they were visualized via transmission electron microscopy and scanning electron microscopy. Effect of the encapsulated amount of Gln was investigated by encapsulating Gln at three different concentrations (i.e0.20 mM, 40 mM and 60 mM). Drug encapsulation and release studies were implemented with high pressure liquid chromatography (HPLC). The encapsulation efficiency of Gln was determined to be the higher than the ones reported in the literature: 83.6%, 87.1% and 84.9% for 20 mM, 40 mM and 60 mM Gln, respectively. It was found that after 6 hours, liposomes loaded with 60 mM of Gln had released 45.7% of Gln. Optical microscopy images of the erythrocytes after 3 hours of incubation and haemolysis measurements proved that presence of liposomes did not cause any structural changes on the erythrocyte shape. Overall, it was concluded that L-Gln loaded PC/PG liposomes provide promising results in terms of developing a new drug delivery platform for SCD.
Collapse
Affiliation(s)
- Gokce Alp
- Department of Chemical Engineering, Faculty of Engineering, Hacettepe University, Ankara, Turkey
| | - Yesim Oztas
- Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| |
Collapse
|
6
|
Schlich M, Lai F, Maria Fadda A, Sinico C, Pini E. Drug-Excipients Compatibility Studies in Proniosomal Formulation: A Case Study with Resveratrol. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY 2021; 21:2917-2921. [PMID: 33653458 DOI: 10.1166/jnn.2021.19056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Proniosomal drug delivery system is one of the advancements in nanotechnology. Similarly to traditional dosage forms, chemical and physical compatibility of proniosomes components with the active ingredient(s) is a key step in the preformulation process of such systems. In this work, the compatibility of resveratrol with selected excipients in the development of proniosomal formulation was investigated by thermal and spectroscopic techniques. To evaluate the drug-excipient compatibility, different techniques such as differential scanning calorimetric study, attenuated total reflectance Fourier transform infrared spectroscopy study and powder X-ray diffraction were adopted. The results showed that the excipients used in the formulation were compatible with resveratrol.
Collapse
Affiliation(s)
- Michele Schlich
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Francesco Lai
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Anna Maria Fadda
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Chiara Sinico
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Elena Pini
- Department of Pharmaceutical Science, University of Milan, Via Venezian 21, 20133, Milan, Italy
| |
Collapse
|
7
|
Khan I, Hussein S, Houacine C, Khan Sadozai S, Islam Y, Bnyan R, Elhissi A, Yousaf S. Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers. Int J Pharm 2021; 598:120376. [PMID: 33617949 DOI: 10.1016/j.ijpharm.2021.120376] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2020] [Revised: 02/04/2021] [Accepted: 02/06/2021] [Indexed: 01/03/2023]
Abstract
Aerosolization is a non-invasive approach in drug delivery for localized and systemic effect. Nanostructured lipid carriers (NLCs) are new generation versatile carriers, which offer protection from degradation and enhance bioavailability of poorly water soluble drugs. The aim of this study was to develop and optimize NLC formulations in combination with optimized airflow rates (i.e. 60 and 15 L/min) and choice of medical nebulizers including Air jet, Vibrating mesh and Ultrasonic nebulizer for superior aerosolization performance, assessed via a next generation impactor (NGI). Novel composition and combination of NLC formulations (F1 - F15) were prepared via ultrasonication method, employing five solid lipids (glycerol trimyristate (GTM), glycerol trilaurate (GTL), cetyl palmitate (CP), glycerol monostearate (GMS) and stearic acid (SA)); and three liquid lipids (glyceryl tributyrate (GTB), propylene glycol dicaprylate/dicaprate (PGD) and isopropyl palmitate (IPP)) in 1:3 w/w ratios (i.e. combination of one solid and one liquid lipid), with Beclomethasone dipropionate (BDP) incorporated as the model drug. Out of fifteen BDP-NLC formulations, the physicochemical properties of formulations F7, F8 and F10 exhibited desirable stability (one week at 25 °C), with associated particle size of ~241 nm, and >91% of drug entrapment. Post aerosolization, F10 was observed to deposit notably smaller sized particles (from 198 to 136 nm, 283 to 135 nm and 239 to 157 nm for Air jet, Vibrating mesh and Ultrasonic nebulizers, respectively) in all stages (i.e. from stage 1 to 8) of the NGI, when compared to F7 and F8 formulations. Six week stability studies conducted at 4, 25 and 45 °C, demonstrated F10 formulation stability in terms of particle size, irrespective of temperature conditions. Nebulizer performance study using the NGI for F10 identified the Air jet to be the most efficient nebulizer, depositing lower concentrations of BDP in the earlier stages (1-3) and higher (circa 82 and 85%) in the lateral stages (4-8) using 60 and 15 L/min airflow rates, when compared to the Vibrating mesh and Ultrasonic nebulizers. Moreover, at both airflow rates, the Air jet nebulizer elicited a longer nebulization time of ~42 min, facilitating aerosol inhalation for prophylaxis of asthma with normal tidal breathing. Based on characterization and nebulizer performance employing both 60 and 15 L/min airflow rates, the Air jet nebulizer offered enhanced performance, exhibiting a higher fine particle dose (FPD) (90 and 69 µg), fine particle fraction (FPF) (70 and 54%), respirable fraction (RF) (92 and 69%), and lower mass median aerodynamic diameter (MMAD) (1.15 and 1.62 µm); in addition to demonstrating higher drug deposition in the lateral parts of the NGI, when compared to its counterpart nebulizers. The F10 formulation used with the Air jet nebulizer was identified as being the most suitable combination for delivery of BDP-NLC formulations.
Collapse
Affiliation(s)
- Iftikhar Khan
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, United Kingdom.
| | - Sozan Hussein
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, United Kingdom
| | - Chahinez Houacine
- School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, United Kingdom
| | - Sajid Khan Sadozai
- Department of Pharmacy, Kohat University of Science and Technology, Kohat, Pakistan
| | - Yamir Islam
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, United Kingdom
| | - Ruba Bnyan
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, United Kingdom
| | - Abdelbary Elhissi
- Pharmaceutical Sciences Section, College of Pharmacy, Qatar University, P.O. Box 2713, Doha, Qatar
| | - Sakib Yousaf
- Department of Pharmacy, Kohat University of Science and Technology, Kohat, Pakistan
| |
Collapse
|
8
|
Khudair N, Agouni A, Elrayess MA, Najlah M, Younes HM, Elhissi A. Letrozole-loaded nonionic surfactant vesicles prepared via a slurry-based proniosome technology: Formulation development and characterization. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.101721] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
9
|
Abbaspour Sani N, Hasani M, Kianmehr A, Mohammadi S, Sheikh Arabi M, Yazdani Y. Enhanced nuclear translocation and activation of aryl hydrocarbon receptor (AhR) in THP-1 monocytic cell line by a novel niosomal formulation of indole-3-carbinol. J Liposome Res 2020; 30:117-125. [PMID: 30917715 DOI: 10.1080/08982104.2019.1600545] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Although niosomes structurally resemble liposomes, they are composed of nonionic surfactants which result in less toxicity and more stability. Here, we developed a novel niosomal formulation of I3C and investigated the nuclear translocation and activation of AhR among human acute myeloid leukaemia (AML) monocytic THP-1 cell line. Niosomal vesicles comprised of nonionic surfactants, cholesterol and I3C were prepared using thin film hydration (TFH) method and characterized according to the entrapment efficiency (EE %), size and zeta potential, by Dynamic light scattering method (DLS), and the surface morphology visualized by Transmission electron microscopy (TEM). In vitro release of I3C was evaluated and MTS assay was used to evaluate the viability of THP-1 cells. The nuclear translocation of AhR was assessed by immunocytochemistry (ICC) and Real-time RT-PCR was conducted using AhR target genes. The ratio of Cholesterol:Span 60 (1:1) niosomal formulations with the highest significant EE% were selected. I3C exerted cytotoxic effects on THP-1 cells in a dose- and time-dependent manner, while administration of niosomal I3C reduced these effects. Both niosomal and free I3C formulations facilitated the nuclear translocation of AhR. CYP1A1 was overexpressed in response to both free and niosomal I3C treatments, while IL1β was overexpressed merely in niosomal I3C-treated THP-1 cells. Niosomal formulation of I3C resulted in reduced cytotoxicity effects by enhancing the functional effects of I3C on AhR in THP-1 cells, including its nuclear translocation and overexpression of the target genes.
Collapse
Affiliation(s)
- Neda Abbaspour Sani
- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran
| | - Mahsa Hasani
- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran
| | - Anvarsadat Kianmehr
- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran
- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
| | - Saeed Mohammadi
- Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran
- Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran
| | - Mehdi Sheikh Arabi
- Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran
| | - Yaghoub Yazdani
- Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran
- Laboratory Science Research Center, Golestan University of Medical Sciences, Gorgan, Iran
| |
Collapse
|
10
|
Najlah M, Said Suliman A, Tolaymat I, Kurusamy S, Kannappan V, Elhissi AMA, Wang W. Development of Injectable PEGylated Liposome Encapsulating Disulfiram for Colorectal Cancer Treatment. Pharmaceutics 2019; 11:pharmaceutics11110610. [PMID: 31739556 PMCID: PMC6920821 DOI: 10.3390/pharmaceutics11110610] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2019] [Revised: 11/07/2019] [Accepted: 11/11/2019] [Indexed: 12/18/2022] Open
Abstract
Disulfiram (DS), an anti-alcoholism medicine, shows strong anti-cancer activity in the laboratory, but the application in clinics for anti-cancer therapy has been limited by its prompt metabolism. Conventional liposomes have shown limited ability to protect DS. Therefore, the aim of this study is to develop PEGylated liposomes of DS for enhanced bio-stability and prolonged circulation. PEGylated liposomes were prepared using ethanol-based proliposome methods. Various ratios of phospholipids, namely: hydrogenated soya phosphatidylcholine (HSPC) or dipalmitoyl phosphatidylcholine (DPPC) and N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG2000) with cholesterol were used. DS was dissolved in the alcoholic solution in different lipid mol% ratios. The size of the resulting multilamellar liposomes was reduced by high-pressure homogenization. Liposomal formulations were characterized by size analysis, zeta potential, drug loading efficiency and stability in horse serum. Small unilamellar vesicles (SUVs; nanoliposomes) were generated with a size of approximately 80 to 120 nm with a polydispersity index (PDI) in the range of 0.1 to 0.3. Zeta potential values of all vesicles were negative, and the negative surface charge intensity tended to increase by PEGylation. PEGylated liposomes had a smaller size (80–90 nm) and a significantly lower PDI. All liposomes showed similar loading efficiencies regardless of lipid type (HSPC or DPPC) or PEGylations. PEGylated liposomes provided the highest drug biostability amongst all formulations in horse serum. PEGylated DPPC liposomes had t1/2 =77.3 ± 9.6 min compared to 9.7 ± 2.3 min for free DS. In vitro cytotoxicity on wild type and resistant colorectal cancer cell lines was evaluated by MTT assay. All liposomal formulations of DS were cytotoxic to both the wild type and resistant colorectal cancer cell lines and were able to reverse chemoresistance at low nanomolar concentrations. In conclusion, PEGylated liposomes have a greater potential to be used as an anticancer carrier for disulfiram.
Collapse
Affiliation(s)
- Mohammad Najlah
- Pharmaceutical Research Group, School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Bishops Hall Lane, Chelmsford CM1 1SQ, UK; (A.S.S.); (I.T.)
- Correspondence: ; Tel.: +44(0)124568-4682
| | - Ammar Said Suliman
- Pharmaceutical Research Group, School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Bishops Hall Lane, Chelmsford CM1 1SQ, UK; (A.S.S.); (I.T.)
| | - Ibrahim Tolaymat
- Pharmaceutical Research Group, School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Bishops Hall Lane, Chelmsford CM1 1SQ, UK; (A.S.S.); (I.T.)
| | - Sathishkumar Kurusamy
- Faculty of Science & Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK; (S.K.); (V.K.); (W.W.)
| | - Vinodh Kannappan
- Faculty of Science & Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK; (S.K.); (V.K.); (W.W.)
| | - Abdelbary M. A. Elhissi
- College of Pharmacy and Office of the Vice President (Research and Graduate Studies), Qatar University, Doha, Qatar;
| | - Weiguang Wang
- Faculty of Science & Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK; (S.K.); (V.K.); (W.W.)
| |
Collapse
|
11
|
Khatoon M, Shah KU, Din FU, Shah SU, Rehman AU, Dilawar N, Khan AN. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv 2017; 24:56-69. [PMID: 29130758 PMCID: PMC8812579 DOI: 10.1080/10717544.2017.1384520] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Vesicular drug delivery systems have gained wide attention in the field of nanotechnology. Among them proniosomes become the superior over other vesicular carriers. Proniosomes are dry formulations of water soluble nonionic surfactant coated carrier system which immediately forms niosomes upon hydration. They have the capability to overcome the instability problems associated with niosomes and liposomes and have the potential to improve solubility, bioavailability, and absorption of various drugs. Furthermore, they offer versatile drug delivery concept for enormous number of hydrophilic and hydrophobic drugs. They have the potential to deliver drugs effectively through different routes at specific site of action to achieve controlled release action and reduce toxic effects associated with drugs. This review discusses the general preparation techniques of proniosomes and mainly focus on the applications of proniosomes in drug delivery and targeting. Moreover, this review demonstrates critical appraisal of the literature for proniosomes. Additionally, this review extensively explains the potential of proniosomes in delivering drugs via different routes, such as oral, parenteral, dermal and transdermal, ocular, oral mucosal, vaginal, pulmonary, and intranasal. Finally, the comparison of proniosomes with niosomes manifests the clear distinction between them. Moreover, proniosomes need to be explored for proteins and peptide delivery and in the field of nutraceuticals and develop pilot plant scale up studies to investigate them in industrial set up.
Collapse
Affiliation(s)
- Maryam Khatoon
- Department of Pharmacy, Quaid-e-Azam University, Islamabad, Pakistan
| | | | - Fakhar Ud Din
- Department of Pharmacy, Quaid-e-Azam University, Islamabad, Pakistan
| | - Shefaat Ullah Shah
- Department of Pharmaceutics, Faculty of Pharmacy, Gomal University, D.I. Khan, Pakistan
| | - Asim Ur Rehman
- Department of Pharmacy, Quaid-e-Azam University, Islamabad, Pakistan
| | - Naz Dilawar
- Department of Pharmacy, Quaid-e-Azam University, Islamabad, Pakistan
| | - Ahmad Nawaz Khan
- School of Chemical and materials Engineering, National University of Sciences and Technology, Islamabad, Pakistan
| |
Collapse
|
12
|
Ahmad MZ, Mohammed AA, Mokhtar Ibrahim M. Technology overview and drug delivery application of proniosome. Pharm Dev Technol 2016; 22:302-311. [PMID: 26794727 DOI: 10.3109/10837450.2015.1135344] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Rapid advancement in the field of colloidal science has shown a great progress in the development of proniosome technology (PT) as an impending drug delivery system. PT is a valuable carrier system for delivery of hydrophobic as well as hydrophilic drugs. It is a liquid crystalline compact niosomal hybrid, which upon hydration gives niosomes. They can augment the bioavailability of encapsulated drug and provide better therapeutic activity in a controlled manner. Non-toxicity, penetration enhancing the effect of surfactant and modified drug release from the proniosomal transdermal gel has attracted a greater attention of formulation scientist toward PT. Free flowing dry proniosomal powder are suitable for unit dosage forms such as tablet and capsules. Proniosomes are auspicious drug delivery system for the future. Proniosomes-derived niosomes are a better alternative to the other vesicular system due to their superior physicochemical stability and effective drug delivery capability. The focus of this review is to bring out all the aspects of proniosomes including their different compositions, various methods of preparation, characterization and recent development in their therapeutic applications.
Collapse
Affiliation(s)
- Mohammad Zaki Ahmad
- a Department of Pharmaceutics , Faculty of Pharmacy, Najran University , Najran , Saudi Arabia and
| | - Abdul Aleem Mohammed
- a Department of Pharmaceutics , Faculty of Pharmacy, Najran University , Najran , Saudi Arabia and
| | - Mahmoud Mokhtar Ibrahim
- a Department of Pharmaceutics , Faculty of Pharmacy, Najran University , Najran , Saudi Arabia and.,b Department of Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Zagazig University , Zagazig , Egypt
| |
Collapse
|